POST COVID PNEUMONIA: MODERN THERAPEUTIC APPROACH BY PULMONARY DRUG DELIVERY DEVICE
B. RAY *
Department of Pharmacology, CPS Puri, Odisha, India.
S. K. MAHAPATRA
IPT Salipur, Odisha, India.
SUBHAM KU. PANDA
P. G. Department of Pharmacy, SPS, SOA University, Odisha, India.
SASWAT NANDA
P. G. Department of Pharmacy, SPS, SOA University, Odisha, India.
*Author to whom correspondence should be addressed.
Abstract
Streptococcus pneumonia (also known as pneumococcal) is a commensal that colonizes the upper respiratory tract and a pathogen that causes intrusive illnesses like otitis media, pneumonia, sepsis, and meningitis. In India, the Invasive Bacterial Infection Surveillance (IBIS) organization and South Asian Pneumococcal Alliance (SAPNA) have been associated with assortment of significant information in regards to serotype dissemination and antimicrobial obstruction of pneumococcal diseases for over 12 years. COVID 19 Patients are much more prone towards this infection, if untreated at appropriate time. So development of New Device are immense Important which contributes rapid and Proper Drug Delivery to lungs. Research must be carried out in the field of Novel Drug Delivery System for target delivery of Drugs like Antibiotic, Bronchodiator and Corticosteroid to Respiratory Tract. The present Review article focus Different grade of Pneumococcal Infection and Infection associated with Post COVID Condition. The article also highlights new devices which helpful for Pulmonary drug delivery which is vital during COVID Associated Pneumococcal Infection.
Keywords: Pneumonia, antimicrobial, corticosteroid, pathogenesis, pulmonary drug delivery